Merck
CN
  • A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation.

A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation.

Proteomes (2021-06-03)
Joel Ricky Steele, Natalie Strange, Kenneth J Rodgers, Matthew P Padula
ABSTRACT

Proteinopathies are protein misfolding diseases that have an underlying factor that affects the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. The presence of levodopa as a protein constituent has been explored in several studies, but it has not been examined in a global proteomic manner. This paper provides a proof-of-concept method for enzymatically creating levodopa-containing proteins using the enzyme tyrosinase and provides spectral evidence of in vitro incorporation in addition to the induction of the unfolded protein response due to levodopa.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Tyrosinase from mushroom, lyophilized powder, ≥1000 unit/mg solid